مشخصات پژوهش

صفحه نخست /Palmitoylethanolamide as ...
عنوان
Palmitoylethanolamide as adjunctive therapy in major depressive disorder: a double-blind, randomized and placebo-controlled trial
نوع پژوهش مقاله چاپ شده
کلیدواژه‌ها
Anti-inflammatory; Glutamate; Major Depressive Disorder (MDD); PPAR-α Agonists; Palmitoylethanolamide (PEA)
چکیده
Background Experimental studies provide evidence for antidepressant effects of Palmitoylethanolamide (PEA) in animal models of depression. We aimed to evaluate the efficacy and tolerability of PEA add-on therapy in treatment of patients with major depressive disorder (MDD). Methods In a randomized double-blind, and placebo-controlled study, 58 patients with MDD (DSM-5) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 600 mg twice daily Palmitoylethanolamide or placebo in addition to citalopram for six weeks. Patients were assessed using the HAM-D scale at baseline and weeks 2, 4, and 6. Results Fifty-four individuals completed the trial. At week 2, patients in the PEA group demonstrated significantly greater reduction in HAM-D scores compared to the placebo group (8.30 ± 2.41 vs. 5.81 ± 3.57, P=0.004). The PEA group also demonstrated significantly greater improvement in depressive symptoms [F (3, 156) =3.35, P=0.021] compared to the placebo group throughout the trial period. The patients in the PEA group experienced more response rate (≥ 50% reduction in the HAM-D score) than the placebo group (100% vs. 74% respectively, P=0.01) at the end of the trial. Baseline parameters and frequency of side effects were not significantly different between the two groups. Limitations The population size in this study was small and the follow-up period was relatively short. Conclusions Palmitoylethanolamide adjunctive therapy to citalopram can effectively improve symptoms of patients (predominantly male gender) with major depressive disorder. PEA showed rapid-onset antidepressant effects which need further investigation.
پژوهشگران علی قلعه ایها (نفر ششم به بعد)